This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Julius-Maximilians-Universitat Wurzburg. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Innovator in Immunotherapy: Andreas Mades
Introduction: Andreas Mades is an accomplished inventor based in Wiesbaden-Biebrich, Germany. He has made significant contributions to the field of immunotherapy through his innovative work in chimeric antigen receptors (CAR). His expertise has led to the development of a breakthrough technology that has the potential to improve cancer treatment options.
Latest Patents: Andreas Mades holds a notable patent titled "ROR1-specific chimeric antigen receptors (CAR) with humanized targeting domains." This invention focuses on CAR technology that incorporates a humanized targeting domain specific to the ROR1 antigen. It includes polynucleotides and vectors that encode these CARs, as well as isolated cells that express them on their surface. This development is particularly significant for its applications in immunotherapy, offering hope for more effective cancer treatments.
Career Highlights: Mades currently works at the Julius Maximilians University of Würzburg, where he collaborates with various researchers to further advance the field of immunotherapy. His dedication to innovation in medicine has positioned him as a key figure in his area of expertise.
Collaborations: One of the prominent collaborations in Mades' career is with Michael Hudecek, a researcher who shares a similar vision for advancing cancer therapies. Together, they work to explore new possibilities in CAR technology and its applications, amplifying the impact of their discoveries on patient care.
Conclusion: In conclusion, Andreas Mades is a pioneering inventor whose work on ROR1-specific chimeric antigen receptors signifies a vital advancement in immunotherapy. His contributions at the Julius Maximilians University of Würzburg, along with his collaboration with Michael Hudecek, illustrate his commitment to enhancing treatment options for cancer patients. As research in this field continues to evolve, the innovations led by Mades are likely to play a crucial role in shaping the future of cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile